Phase II Clinical trail on Chronic myelogenous leukemia (cancer of while blood cells) in children from 2 years to 18 years of age.
- Conditions
- Health Condition 1: null- Chronic Myelogenous Luekemia
- Registration Number
- CTRI/2011/08/001975
- Lead Sponsor
- BristolMyers Squibb India Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 110
Inclusion criterias:
1)Age 2 to 18 years.
2)Lansky or Karnofsky scale >50.
3)Life expectancy more than 12 weeks.
4)Any toxicity from recent therapies recovered to baseline or grade 1.
5)Adequate hepatic and renal function.
Prior therapy with dasatinib
Eligible for potentially curative therapy including hematopoietic stem-cell transplantation
Symptomatic central nervous system disease
Isolated extramedullary disease
Medical condition significantly impairing ability of patient to receive dasatinib
T315I mutation in BCR-AB
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.